UTHR vs. ALNY, REGN, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, IONS, and MDGL
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Alnylam Pharmaceuticals (ALNY), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Ionis Pharmaceuticals (IONS), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry.
United Therapeutics vs. Its Competitors
Alnylam Pharmaceuticals (NASDAQ:ALNY) and United Therapeutics (NASDAQ:UTHR) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, media sentiment, earnings, dividends, profitability, valuation and risk.
93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.2% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 10.3% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
United Therapeutics has a net margin of 40.36% compared to Alnylam Pharmaceuticals' net margin of -12.96%. United Therapeutics' return on equity of 18.73% beat Alnylam Pharmaceuticals' return on equity.
Alnylam Pharmaceuticals presently has a consensus price target of $439.58, indicating a potential downside of 4.10%. United Therapeutics has a consensus price target of $438.85, indicating a potential upside of 0.02%. Given United Therapeutics' higher possible upside, analysts clearly believe United Therapeutics is more favorable than Alnylam Pharmaceuticals.
Alnylam Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500. Comparatively, United Therapeutics has a beta of 0.62, meaning that its stock price is 38% less volatile than the S&P 500.
In the previous week, United Therapeutics had 3 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 29 mentions for United Therapeutics and 26 mentions for Alnylam Pharmaceuticals. United Therapeutics' average media sentiment score of 0.79 beat Alnylam Pharmaceuticals' score of 0.70 indicating that United Therapeutics is being referred to more favorably in the news media.
United Therapeutics has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
United Therapeutics beats Alnylam Pharmaceuticals on 13 of the 16 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding UTHR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
United Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UTHR) was last updated on 9/24/2025 by MarketBeat.com Staff